Basma

Basma, on behalf of Marc Goodman, asked about the interim look status for the Panorama and Emerge trials. She also sought clarification on Definium's expectations for the GAD remission rate and what would be considered a good and differentiated rate compared to standard of care.

Answer

Robert Barrow, CEO, confirmed that the Panorama update would be provided at the upcoming Analyst Day, and no interim looks are planned for the MDD studies (Emerge is fully enrolled). Dr. Daniel Karlin, Chief Medical Officer, discussed typical SRI remission rates in MDD and explained that Phase 3 GAD and MDD studies are designed to target open-label treatment to keep patients in a mild or better illness range, rather than specifying an absolute remission rate a priori.

Basma, on behalf of Marc Goodman from Leerink Partners, asked if an interim look for the Panorama study had been conducted or was planned, and if an interim look was scheduled for the Emerge MDD trial. She also inquired about Definium's expectations for the GAD remission rate and what would be considered a differentiated rate compared to standard of care.

Answer

Robert Barrow, CEO, confirmed that Panorama updates, including interim look details, would be shared at the April Analyst Day, and no interim look is planned for the fully enrolled Emerge MDD trial. Daniel Karlin, CMO, explained that while MDD remission rates for SRIs are typically 10-30%, for GAD, Definium's Part B design aims to move patients into a mild or better illness range with redosing, rather than setting an a priori absolute remission rate.